Tonix Pharmaceuticals Holding Corp. (TNXP): Nasdaq/NYSE listing notice — Tonix receives Nasdaq deficiency notice for minimum bid price; 180-day cure period

Tonix Pharmaceuticals Holding Corp.

Received Nasdaq notice on Oct 25, 2022 for non-compliance with minimum bid price $1 per share.
Has until April 24, 2023 to regain compliance; bid price must close at $1+ for 10 consecutive days.
If unmet, may seek additional 180-day period by meeting other listing standards and filing cure intent.
Stock not immediately delisted; company monitoring price and evaluating options to cure.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Tonix Pharmaceuticals Holding Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

October 25, 2022, the Company received a letter (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq listing rules, the Company has been provided a period of 180 calendar days, or until April 24, 2023, in which to regain complianc

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001387131-22-010938

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.